Skip to main content
LXRX
NASDAQ Life Sciences

Sotagliflozin Shows Consistent Heart Failure Benefit Across Blood Pressure Levels

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.3
Mkt Cap
$1.019B
52W Low
$1.03
52W High
$2.68
52W Position info
123% above low
Off High info
14% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LXRX has more than doubled off its 52-week low of $1.03.

Summary

Lexicon presented a post hoc analysis of the Phase 3 SOLOIST-WHF trial at ESC Congress 2026, showing sotagliflozin reduced cardiovascular death and heart failure events consistently across baseline systolic blood pressure levels. In the lowest blood pressure subgroup (SBP <110 mmHg), the hazard ratio was 0.56 (p=0.03), with no increase in hypotension or acute kidney injury. This is the first report of these data, which were simultaneously published in JACC: Heart Failure. The results strengthen the case for sotagliflozin in a high-risk heart failure population and support its potential label expansion. The company is also advancing sotagliflozin in the Phase 3 SONATA-HCM study for hypertrophic cardiomyopathy, with top-line data expected in 2027.

At the time of this announcement, LXRX was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.03 to $2.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

LXRX - Latest Insights

LXRX
Nov 05, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.78 info
Change: +$0.1619 (+10%) info
Market Cap: $792.518M info
LXRX
Nov 05, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.78 info
Change: +$0.165 (+10%) info
Market Cap: $792.518M info
LXRX
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.78 info
Change: +$0.165 (+10%) info
Market Cap: $792.518M info
LXRX
Aug 24, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $1.78 info
Change: -$0.605 (-25%) info
Market Cap: $792.518M info
LXRX
Aug 06, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.78 info
Change: -$0.175 (-9%) info
Market Cap: $792.518M info